Global Medical Institutes, Llc

Princeton, New Jersey 08540

0 studies enrolling now · 15 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder, Central Nervous System Diseases, Depressive Episodes, Bipolar I Depression, Epilepsy, Influenza A, Insomnia, Major Depressive Disorder, Restless Legs Syndrome, Treatment Resistant Depression

Studies at this site

• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD — Completed
• A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. — Stopped early
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
• A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults — Completed
• Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia — Completed
• Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS) — Completed
• Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic — Completed
• Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants — Completed
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease — Stopped early
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease — Completed
• Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease — Completed